Want to take quizzes and track your credits?
In a previous cohort study, administration of the BNT162b2 vaccine in patients with solid tumors demonstrated a favorable safety and efficacy profile following the second vaccination, although gradual immunogenicity was observed compared with the general population.1 We had previously demonstrated at 6 months postvaccination a steady decline in antibody titers and seropositivity rates among patients with solid tumors treated at a center in Haifa, Israel, that were comparable with the general population.2 Because of declined immunity, a booster dose had been recommended by medical authorities.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: March 30, 2022.
Published Online: April 22, 2022. doi:10.1001/jamaoncol.2022.1467
Corresponding Author: Irit Ben-Aharon, MD, PhD, Division of Oncology, Rambam Health Care Campus, HaAliya HaShniya 8, Haifa, Israel 31096 (email@example.com).
Author Contributions: Dr Ben-Aharon had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Waldhorn and Holland contributed equally.
Concept and design: Waldhorn, Ben-Aharon, Goshen-Lago, Halberthal.
Acquisition, analysis, or interpretation of data: Waldhorn, Ben-Aharon, Goshen-Lago, Holland, Benguigui, Shaked.
Drafting of the manuscript: Waldhorn, Ben-Aharon, Goshen-Lago, Holland, Shaked.
Critical revision of the manuscript for important intellectual content: Waldhorn, Ben-Aharon, Halberthal, Benguigui.
Statistical analysis: Waldhorn, Ben-Aharon, Holland.
Obtained funding: Ben-Aharon.
Administrative, technical, or material support: Ben-Aharon, Goshen-Lago, Benguigui.
Supervision: Ben-Aharon, Halberthal, Shaked.
Conflict of Interest Disclosures: Dr Goshen-Lago reported grants from the Israel Cancer Research Fund during the conduct of the study. No other disclosures were reported.
Role of the Funder/Sponsor: The funding organization (Israel Cancer Research Fund) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.
You currently have no courses saved.